Givatayim, Israel, November 16, 2026
Eocene Ltd. and Barcode Nanotech have reported progress in developing a novel tumor microenvironment-targeted lipid nanoparticle (LNP) formulation of Aramchol, an investigational therapeutic molecule being explored for potential applications in liver and gastrointestinal (GI) cancers. The development is being conducted through Eocene’s wholly owned subsidiary, Galmed Research & Development Ltd., using Barcode Nanotech’s proprietary tumor-targeting lipid nanoparticle delivery platform. The new formulation is designed to redirect Aramchol’s biodistribution toward the tumor microenvironment (TME), with the objective of selectively targeting cells involved in fibrosis. The companies believe that targeting fibrosis within the tumor microenvironment could potentially improve the effectiveness of immunotherapy and other standard cancer treatments. The formulation has been developed using FDA-approved lipids, although this does not mean that the resulting drug formulation has received FDA approval. The collaboration represents an emerging research approach combining pharmaceutical formulation development, nanotechnology, and targeted drug delivery to investigate potential new strategies for treating difficult-to-manage cancers.
Lipid Nanoparticle Technology Targets the Tumor Microenvironment
The tumor microenvironment is a complex biological environment surrounding cancer cells that includes immune cells, blood vessels, fibroblasts, and other supporting structures. These components interact with tumor cells and can influence cancer progression, immune responses, and treatment effectiveness. In certain cancers, particularly those associated with chronic inflammation and tissue damage, fibrosis can contribute to the formation of a protective environment that limits immune-cell activity and reduces responsiveness to treatment. Although existing cancer therapies, including immune checkpoint inhibitors and angiogenesis inhibitors, target different components of the tumor microenvironment, Eocene believes that directly addressing fibrosis could provide another therapeutic strategy. To investigate this possibility, Galmed is working with Barcode Nanotech to use its proprietary lipid nanoparticle formulation technology to deliver Aramchol toward the tumor microenvironment in liver and GI tumors. Lipid nanoparticles are nanoscale delivery systems composed of lipid-based materials that can be engineered to influence how therapeutic molecules are distributed throughout the body. The companies aim to use this technology to improve the localization of Aramchol in tumor-associated tissues and selectively affect cells that contribute to fibrosis. By changing the drug’s distribution, the new formulation is intended to enhance its antifibrotic activity in the targeted environment. This approach is particularly relevant to research into combination cancer therapies, where modifying the tumor microenvironment could potentially make tumors more responsive to existing treatments.
Aramchol’s Earlier Clinical Research Supports Further Investigation
Aramchol is a synthetic fatty acid-bile acid conjugate molecule previously investigated for its potential antifibrotic properties in liver disease. According to Eocene, earlier studies of orally administered Aramchol demonstrated improvements in liver fibrosis among patients with non-alcoholic steatohepatitis (NASH), now also known as metabolic dysfunction-associated steatohepatitis (MASH). These findings were reported in the randomized, double-blind, placebo-controlled Phase IIb ARREST study and an open-label extension associated with the Phase III ARMOR study. The company is now exploring whether the molecule’s previously investigated antifibrotic properties can be applied to oncology through a different formulation and delivery strategy. Rather than relying on the distribution achieved by the oral formulation, the new LNP approach is intended to direct Aramchol toward fibrosis-associated cells within the tumor microenvironment. Eocene aims to enhance and accelerate the antifibrotic effects observed with oral Aramchol by using Barcode’s tumor-targeting delivery technology. However, the earlier liver-disease research does not establish the effectiveness of the new formulation against cancer. The cancer-targeted Aramchol LNP formulation represents a separate research-stage development that requires further preclinical evaluation and clinical investigation.
Eocene and Barcode Expand Targeted Drug Delivery Research
The collaboration also highlights the growing role of nanotechnology and artificial intelligence-assisted drug delivery research in pharmaceutical development. Barcode Nanotech develops delivery solutions through its proprietary NeoRNAâ„¢ Targeting Technology, which combines lipid design, computational tools, and in vivo screening to identify and optimize lipid nanoparticle formulations for different target tissues. Its platform uses multiplexed screening and biodistribution analysis to investigate how therapeutic molecules can be directed toward specific organs and cell populations. Through the collaboration, the companies are applying this expertise to investigate Aramchol delivery to the tumor microenvironment in liver and gastrointestinal cancers. The potential objective is to address fibrosis-associated barriers that may limit the effectiveness of immunotherapy and other standard treatment approaches. The development could provide a new direction for targeted antifibrotic drug delivery in oncology, although its therapeutic value remains to be established through additional research. Further studies will be necessary to assess biodistribution, safety, biological activity, and potential treatment benefits before clinical development can be considered. The announcement therefore represents an early pharmaceutical research milestone rather than a demonstrated cancer treatment breakthrough.
Source: Eocene, Barcode Nanotech press release



